Estradiol

(redirected from Estradiol transdermal system)
Also found in: Dictionary, Medical.

estradiol

[‚es·trə′dī‚ȯl]
(biochemistry)
C18H24O2 An estrogenic hormone produced by follicle cells of the vertebrate ovary; provokes estrus and proliferation of the human endometrium, and stimulates ICSH (interstitial-cell-stimulating hormone) secretion.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Estradiol

 

C18H24O2, a female sex hormone of the estrogen group with the structural formula

Estradiol occurs as colorless crystals with a melting point of 176°–178°C. Poorly soluble in water, it dissolves better in organic solvents. It is optically active, with a specific rotation of [α]D= +81°.

Estradiol was first isolated in 1935 from the follicular fluid of the ovaries of swine by the American biochemist E. Doisy. Of all the estrogens, it has the highest physiological activity, but it is rapidly inactivated in the body. Longer-acting preparations of estradiol (estradiol dipropionate and estradiol benzoate) are obtained by the esterization of estradiol with various organic acids. Estradiol has important physiological functions (seeESTROGEN).

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
The company said the Estradiol Transdermal System USP is the generic version of Novartis' Vivelle-DOT.
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the market launch of its US Food and Drug Administration (FDA) approved XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day).
M2 PHARMA-April 17, 2014-Mylan unveils US FDA approved XULANE (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg per day) for the prevention of pregnancy
Beresford and colleagues compared VTE incidence for up to 90 days in 27,018 women who began taking oral estrogen only, and in 27,018 who began using an estradiol transdermal system (ETS) between January 2002 and October 2009.
Use of the norelgestromin/ethinyl estradiol transdermal system (Ortho-Evra) on an 84-day cycle delayed the median time to first bleeding by 54 days among healthy, normally menstruating women, according to data collected by Felicia Stewart, M.D., codirector of the Center for Reproductive Health Research and Policy at the University of California, San Francisco, and her associates.
In late winter Mylan became the first company to receive approval to produce and market estradiol transdermal system 0.1 mg./day, and 0.05 mg./day (once-a-week formulation).
The newest drug-in-adhesive transdermal patch for ET, Minivelle [R] (estradiol transdermal system), contains estradiol in the same DOT matrix adhesive platform as Vivelle-Dot[R].
Noven Pharmaceutical, a developer and manufacturer of slow-release adhesive patches for skin or oral cavity use, announced yesterday that it has launched its Minivelle (estradiol transdermal system) in the United States.
Use of the norelgestromin ethinyl estradiol transdermal system (Ortho-Evra) on an 84-day cycle delayed the median time to first bleeding by 54 days among healthy, normally menstruating women, according to data collected by Dr.